Literature DB >> 10919640

Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53.

K Shiraishi1, S Fukuda, T Mori, K Matsuda, T Yamaguchi, C Tanikawa, M Ogawa, Y Nakamura, H Arakawa.   

Abstract

Fractalkine is a CX3C-type chemokine that induces chemotaxis of monocytes and cytotoxic T cells. Using the differential display method for examining gene expression in p53-defective cells transfected by adenovirus containing wild-type p53, we observed that fractalkine was induced by ectopic expression of p53. An electrophoretic mobility shift assay showed that a potential p53-binding site present in the promoter of the fractalkine gene could bind to p53 protein. Moreover, a heterogeneous reporter assay indicated that this promoter sequence possessed p53-dependent transcriptional activity. The strong induction of fractalkine when p53 protein was expressed by a wild-type transgene in p53-defective cells brought to light a novel role for p53; that is, potential elimination of damaged cells by the host immune response system through transcriptional regulation of fractalkine. Our results imply a pivotal role of p53 in immunosurveillance to prevent cells from undergoing malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919640

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages.

Authors:  Michael Miksa; Dhruv Amin; Rongqian Wu; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

2.  Differential recognition of response elements determines target gene specificity for p53 and p63.

Authors:  Motonobu Osada; Hannah Lui Park; Yuichi Nagakawa; Keishi Yamashita; Alexey Fomenkov; Myoung Sook Kim; Guojun Wu; Shuji Nomoto; Barry Trink; David Sidransky
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  Regulation and function of SIRT1 in rheumatoid arthritis synovial fibroblasts.

Authors:  Anna Engler; Clare Tange; Mojca Frank-Bertoncelj; Renate E Gay; Steffen Gay; Caroline Ospelt
Journal:  J Mol Med (Berl)       Date:  2015-08-23       Impact factor: 4.599

4.  Cyclin K as a direct transcriptional target of the p53 tumor suppressor.

Authors:  Toshiki Mori; Yoshio Anazawa; Kuniko Matsui; Seisuke Fukuda; Yusuke Nakamura; Hirofumi Arakawa
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

5.  Identification of semaphorin3B as a direct target of p53.

Authors:  Kensuke Ochi; Toshiki Mori; Yoshiaki Toyama; Yusuke Nakamura; Hirofumi Arakawa
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

6.  Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons.

Authors:  Anna Cook; Randi Hippensteel; Saori Shimizu; Jaclyn Nicolai; Alessandro Fatatis; Olimpia Meucci
Journal:  J Biol Chem       Date:  2010-02-02       Impact factor: 5.157

7.  Regulation of MCP-1 chemokine transcription by p53.

Authors:  Katrin Hacke; Bladimiro Rincon-Orozco; Gilles Buchwalter; Simone Y Siehler; Bohdan Wasylyk; Lisa Wiesmüller; Frank Rösl
Journal:  Mol Cancer       Date:  2010-04-20       Impact factor: 27.401

8.  Allele-specific regulation of mutant Huntingtin by Wig1, a downstream target of p53.

Authors:  Sun-Hong Kim; Neelam Shahani; Byoung-Ii Bae; Juan I Sbodio; Youjin Chung; Kazuhiro Nakaso; Bindu D Paul; Akira Sawa
Journal:  Hum Mol Genet       Date:  2016-05-19       Impact factor: 6.150

9.  Unravelling mechanisms of p53-mediated tumour suppression.

Authors:  Kathryn T Bieging; Stephano Spano Mello; Laura D Attardi
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

10.  CX3CL1 promotes breast cancer via transactivation of the EGF pathway.

Authors:  Manuel Tardáguila; Emilia Mira; Miguel A García-Cabezas; Anna M Feijoo; Miguel Quintela-Fandino; Iñigo Azcoitia; Sergio A Lira; Santos Mañes
Journal:  Cancer Res       Date:  2013-05-29       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.